What is your experience with liposomal-encapsulated daunorubicin and cytarabine (CPX-351) for first line treatment of therapy-related AML or AML with myelodysplasia-related changes in elderly patients?   

Do you have experience administering these agents in the outpatient setting?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Community Practice